Showing 877 results
-
Story /For Carter Jaynes, helping to produce doses of RLT is deeply personal. See how a move to our new RLT facility in Carlsbad can help him reach even more patients.
-
Media Release /Phase III ALIGN study results showed reduced rate of kidney function decline by ~34% with Vanrafia vs placebo, based on supportive eGFR slope analysis1 Vanrafia reduced protein in urine by 38.3%…
-
Story /The hidradenitis suppurativa (HS) Community Mapping Project surveyed patients to create a roadmap for change. Here's what they shared.
-
Media Release /Clinically meaningful, statistically significant efficacy achieved in primary and all secondary endpoints, including reduced steroid use; safety consistent with established Cosentyx profile1,2…
-
Biography /
-
Media Release /Growing improvement in major molecular response (MMR) rates demonstrated with Scemblix vs. all standard-of-care TKIs including imatinib and second generation (2G) TKIs1 Clinically relevant 15.2%…
-
Media Release /Addition of Kisqali® (ribociclib) to endocrine therapy (ET) demonstrated a 28% risk reduction in invasive disease-free survival (iDFS) in subgroup of patients with node-negative (N0) disease…
-
Media Release /In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine)…
